Trehalose - Bioblast Pharma

Drug Profile

Trehalose - Bioblast Pharma

Alternative Names: Cabaletta; Trehalose dihydrate

Latest Information Update: 11 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bioblast Pharma
  • Class Disaccharides; Glucans; Small molecules
  • Mechanism of Action Autophagy stimulants; Protein aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oculopharyngeal muscular dystrophy; Spinocerebellar degeneration
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Oculopharyngeal muscular dystrophy
  • Phase II Spinocerebellar degeneration
  • Discontinued Spinal muscular atrophy

Most Recent Events

  • 11 Sep 2017 Discontinued - Preclinical for Spinal muscular atrophy in Israel (IV)
  • 05 Jun 2017 Trehalose is available for licensing as of 12 Jun 2017.
  • 05 Jun 2017 Bioblast Pharma has patent protection for use of trehalose in treatment of Huntington's disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top